Latest Biotechnology News

Page 9 of 115
Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.
Victor Sage
Victor Sage
16 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.
Victor Sage
Victor Sage
16 Oct 2026
Cynata Therapeutics has opened a fully underwritten $913,000 entitlement offer to fund adviser, director and consultant fees, offer costs and working capital. Eligible shareholders can buy three new shares for every eight held, with free options attached.
Ada Torres
Ada Torres
16 Oct 2026
Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.
Ada Torres
Ada Torres
15 Oct 2026
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
Victor Sage
14 Oct 2026
Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
Ada Torres
13 Oct 2026
Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.
Ada Torres
Ada Torres
13 Oct 2026
The US FDA has supported six of seven elements NeuroScientific Biopharmaceuticals put forward for its planned StemSmart Phase 2 Crohn’s disease trial. The remaining issue is a manufacturing control for viral contamination, while trial commencement remains targeted for the end of 2026 and subject to further requirements.
Ada Torres
Ada Torres
13 Oct 2026
Memphasys has reported record September-quarter invoiced revenue of A$211,000 as its Felix fertility device moves into more international markets. The commercial progress comes alongside A$3.5 million in funding, but the loan still requires shareholder approval for conversion into notes.
Ada Torres
Ada Torres
13 Oct 2026
Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.
Ada Torres
Ada Torres
13 Oct 2026
Cynata Therapeutics has lodged a replacement prospectus for a fully underwritten $913,000 entitlement offer, with the cash earmarked largely for adviser costs, intellectual property maintenance and working capital. The raising gives the biotech a near-term funding bridge, but the prospectus again flags a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
12 Oct 2026

Browse the archive

Full archive